Skip to content Skip to footer
Subscribe Now
Alumis & Kaken
News

Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan

Shots:Alumis & Kaken have partnered to develop, manufacture, & market ESK-001 for dermatology in Japan, with an option to expand into rheumatology & GI diseasesAs per the deal, Kaken will handle development, approval & marketing of ESK-001 in Japan in exchange for $40M upfront & near-term co-development costs, with ~$140M in milestones & field…
March 25, 2025

Read more

PharmaShots Interview Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology
VIEWPOINTS

PharmaShots Interview: Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology

In an interview with PharmaShots, Alyssa Johnsen, MD, Ph.D., Vice President, Rheumatology and Maternal-Fetal Health Disease Area Leader at Janssen Research & Development shares her views on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in ACR 2021 and published in Arthritis & RheumatologyShots:The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739…
January 4, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]